Illinois Dentist Loses Federal License for Controlled Substances
Published Date: 9/19/2025
Notice
Summary
Eric Andersen, a dentist from Illinois, lost his DEA license to handle controlled substances because he no longer has the state permission to do so. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration in 2025. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Eric Andersen
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FA2687765 issued to Eric Andersen, D.D.S., because his Illinois dental license and controlled-substance authorizations were revoked on November 25, 2024. The DEA issued an Order to Show Cause on March 18, 2025; Andersen did not request a hearing, and the revocation is effective October 20, 2025.
Pending DEA Applications Denied for Andersen
The DEA also denied any pending applications of Eric Andersen, D.D.S., to renew or modify Registration No. FA2687765 and denied any other pending applications for additional registration in Illinois. That denial is part of the Order effective October 20, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-18170 — Octamethylcyclotetrasiloxane (D4); Draft Risk Evaluation; Science Advisory Committee on Chemicals (SACC) Peer Review; Notice of SACC Meeting; Availability of Draft Documents and Request for Comment
The EPA is holding two virtual meetings in late 2025 to review the safety of a chemical called D4, which is used in many products. They want experts and the public to check their draft report and share thoughts before final decisions. This could affect companies using D4 and might lead to new rules to keep people and the environment safe.
Next: 2025-18172 — Haroon Hameed, M.D.; Decision and Order
Dr. Haroon Hameed from Maryland lost his DEA license because he abused drugs while treating patients and lied on his renewal application. The DEA decided his actions put the public at risk, so they revoked his registration and denied any future applications. This means he can’t legally prescribe controlled substances anymore, effective immediately.